Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 2
2013 2
2015 1
2016 1
2017 2
2018 1
2019 3
2020 4
2021 3
2022 3
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Taxane resistance in breast cancer: a closed HER2 circuit?
de Hoon JP, Veeck J, Vriens BE, Calon TG, van Engeland M, Tjan-Heijnen VC. de Hoon JP, et al. Biochim Biophys Acta. 2012 Apr;1825(2):197-206. doi: 10.1016/j.bbcan.2012.01.001. Epub 2012 Jan 18. Biochim Biophys Acta. 2012. PMID: 22280939 Review.
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2- metastatic breast cancer: an observational study of the SONABRE Registry.
Meegdes M, Geurts SME, Erdkamp FLG, Dercksen MW, Vriens BEPJ, Aaldering KNA, Pepels MJAE, van de Winkel LMH, Peters NAJB, Tol J, Heijns JB, van de Wouw AJ, de Fallois AJO, van Kats MACE, Tjan-Heijnen VCG. Meegdes M, et al. Among authors: vriens bepj. Lancet Reg Health Eur. 2023 Jan 6;26:100573. doi: 10.1016/j.lanepe.2022.100573. eCollection 2023 Mar. Lancet Reg Health Eur. 2023. PMID: 36895447 Free PMC article.
Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls.
Aarnoutse R, Hillege LE, Ziemons J, De Vos-Geelen J, de Boer M, Aerts EMER, Vriens BEPJ, van Riet Y, Vincent J, van de Wouw AJ, Le GN, Venema K, Rensen SS, Penders J, Smidt ML. Aarnoutse R, et al. Among authors: vriens bepj. Cancers (Basel). 2021 Dec 9;13(24):6200. doi: 10.3390/cancers13246200. Cancers (Basel). 2021. PMID: 34944820 Free PMC article.
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy.
Aarnoutse R, Ziemons J, Hillege LE, de Vos-Geelen J, de Boer M, Bisschop SMP, Vriens BEPJ, Vincent J, van de Wouw AJ, Le GN, Venema K, Rensen SS, Penders J, Smidt ML. Aarnoutse R, et al. Among authors: vriens bepj. NPJ Breast Cancer. 2022 Jul 29;8(1):89. doi: 10.1038/s41523-022-00455-5. NPJ Breast Cancer. 2022. PMID: 35906259 Free PMC article.
The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
Meegdes M, Geurts SME, Erdkamp FLG, Dercksen MW, Vriens BEPJ, Aaldering KNA, Pepels MJAE, van de Winkel LMH, Teeuwen NJA, de Boer M, Tjan-Heijnen VCG. Meegdes M, et al. Among authors: vriens bepj. Int J Cancer. 2022 Jan 1;150(1):124-131. doi: 10.1002/ijc.33785. Epub 2021 Sep 14. Int J Cancer. 2022. PMID: 34460112 Free PMC article.
The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, Dercksen MW, Vriens BEPJ, Aaldering KNA, Pepels MJAE, van de Winkel LMH, Tol J, Heijns JB, van de Wouw AJ, Peters NAJB, Hochstenbach-Waelen A, Smidt ML, Geurts SME, Tjan-Heijnen VCG. Meegdes M, et al. Among authors: vriens bepj. Breast Cancer Res Treat. 2022 Apr;192(2):331-342. doi: 10.1007/s10549-021-06472-5. Epub 2022 Jan 13. Breast Cancer Res Treat. 2022. PMID: 35025003 Free PMC article.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group. van der Voort A, et al. Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5. Lancet Oncol. 2024. PMID: 38588682 Clinical Trial.
Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes.
Hackert MQN, van Uden-Kraan CF, Agterof MJ, van der Velden AWG, Vriens BEPJ, Janssen JJB, Geenen M, van der Padt-Pruijsten A, van de Garde EMW. Hackert MQN, et al. Among authors: vriens bepj. Cancer Treat Res Commun. 2023;35:100691. doi: 10.1016/j.ctarc.2023.100691. Epub 2023 Feb 14. Cancer Treat Res Commun. 2023. PMID: 36913809 Free article.
Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.
Ibragimova KIE, Geurts SME, Laczkó D, Meegdes M, Erdkamp F, Heijns JB, Tol J, Vriens BEPJ, Aaldering KNA, Dercksen MW, Pepels MJAE, Peters NAJB, van de Winkel LMH, van de Wouw AJ, de Fallois A, van Kats MACE, Tjan-Heijnen VCG. Ibragimova KIE, et al. Among authors: vriens bepj. Clin Breast Cancer. 2024 Feb;24(2):103-111. doi: 10.1016/j.clbc.2023.10.009. Epub 2023 Nov 2. Clin Breast Cancer. 2024. PMID: 38007349 Free article.
26 results